Treatment with DACOGEN
Indicated in a Broad Range of MDS Patients1
DACOGEN®(decitabine) for Injection is a hypomethylating agent indicated to
treat a broad range of patients1 with myelodysplastic syndromes (MDS), including
- Previously treated and untreated MDS
- De novo and secondary MDS
- All French-American-British (FAB) subtypes (RA, RARS, RAEB, RAEB-t, CMML)
- Intermediate-1, Intermediate-2, and High-risk International Prognostic Scoring System
(IPSS) groups.3
Superior Clinical Results
In a phase III
clinical trial, DACOGEN plus supportive care was proven superior to supportive care alone in treating
patients with MDS, demonstrating the following:
Continuance of Treatment
DACOGEN targets DNA.9 Treatment with DACOGEN should continue
beyond first response and until disease progression.10 It is recommended
that patients be treated with a minimum of 4 cycles; however, a complete or partial
response may take longer than 4 cycles. Treatment with DACOGEN may be continued
as long as the patient continues to benefit.1
Learn more about transfusion independence or visit one of the following pages
to read more about DACOGEN for the treatment of MDS:
*Abbreviations: RA = refractory anemia; RARS = refractory anemia with ringed
sideroblasts; RAEB = refractory anemia with excess blasts; RAEB-t = refractory anemia
with excess blasts in transformation; CMML = chronic myelomonocytic leukemia; CR
= complete response; PR = partial response.
*CR defined as <5% blasts in bone marrow; Hgb >11, ANC ≥1,500, platelets
>100,000, no blasts; no dysplasia; no transfusions or growth factors; minimum
duration 8 weeks.9
†PR defined as 50% decrease in bone marrow blasts, other response criteria
same as CR< or a downgrade in the FAB category.9
IMPORTANT SAFETY INFORMATION
DACOGEN may cause fetal harm when administered to a pregnant woman. Women of childbearing
potential should be advised to avoid becoming pregnant while using DACOGEN. Men
should be advised not to father a child while receiving treatment with DACOGEN,
and for 2 months afterwards. The most commonly occurring adverse reactions include
neutropenia, thrombocytopenia, anemia, pyrexia, fatigue, nausea, cough, petechiae,
constipation, diarrhea, and hyperglycemia.
DACOGEN is available by prescription only. Please see the important product information
for DACOGEN for more information. This site does not contain everything that is
known about DACOGEN. If you would like to know more, talk to your healthcare professional.
This web site contains information relating to various medical conditions and their
treatment. Such information is provided for educational purposes only and is not
meant to be a substitute for the advice of a physician or other health care professional.
You should not use this information for diagnosing a health problem or disease.
Individual responses to DACOGEN treatment may vary.
This site is intended for health care professionals in the United States only. The
products discussed herein may have different product labeling in different countries.
All information collected in this Web site is held in strictest confidence and will
only be used for purposes as specified and will not be sold or distributed to other
parties.